Sg Americas Securities, LLC Nurix Therapeutics, Inc. Call Options Transaction History
Sg Americas Securities, LLC
- $24.1 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NRIX
# of Institutions
174Shares Held
77.7MCall Options Held
126KPut Options Held
11.3K-
Black Rock Inc. New York, NY6.82MShares$68.3 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.06MShares$60.8 Million2.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.47MShares$44.7 Million0.0% of portfolio
-
Commodore Capital LP New York, NY3.95MShares$39.6 Million4.19% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$38.9 Million0.45% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $472M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...